--- title: "Avita Medical | 8-K: FY2025 Q4 Revenue: USD 17.62 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/275809636.md" datetime: "2026-02-12T21:23:53.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275809636.md) - [en](https://longbridge.com/en/news/275809636.md) - [zh-HK](https://longbridge.com/zh-HK/news/275809636.md) --- # Avita Medical | 8-K: FY2025 Q4 Revenue: USD 17.62 M Revenue: As of FY2025 Q4, the actual value is USD 17.62 M. EPS: As of FY2025 Q4, the actual value is USD -0.38, beating the estimate of USD -0.4015. ### Fourth Quarter 2025 Financial Highlights #### Total Revenue AVITA Medical, Inc. reported total revenue of $17.6 million in the fourth quarter of 2025, a decrease from $18.4 million in the fourth quarter of 2024, primarily due to reimbursement headwinds . Sales revenue was $17,431 thousand, and lease revenue was $185 thousand . #### Gross Profit Margin The gross profit margin was 81.2% for the fourth quarter of 2025, compared to 87.6% in Q4 2024, reflecting product mix and inventory-related adjustments . The RECELL-only gross margin for the quarter was 83.1% . #### Operating Expenses Total operating expenses decreased by 5% to $24.7 million in Q4 2025, from $26.1 million in Q4 2024 . Sales and marketing expenses were - $11,938 thousand, general and administrative expenses were - $7,090 thousand, and research and development expenses were - $5,691 thousand . #### Operating Loss The operating loss for Q4 2025 was - $10,407 thousand, compared to - $9,957 thousand in Q4 2024 . #### Net Loss The net loss was - $11.6 million in Q4 2025, consistent with - $11.6 million in Q4 2024 . #### Net Use of Cash Net use of cash improved for the second consecutive quarter to approximately $5.1 million in Q4 2025, compared to $6.2 million in the third quarter and $10.1 million in the second quarter . #### Cash and Marketable Securities AVITA Medical, Inc. ended Q4 2025 with $18.2 million in cash and marketable securities, down from $23.3 million at the start of the quarter and $35.9 million at the end of 2024 . Cash and cash equivalents were $10,243 thousand, and marketable securities were $7,942 thousand as of December 31, 2025 . ### Full-Year 2025 Financial Highlights #### Total Revenues Total revenues for the full year 2025 increased by 11% to $71.6 million, up from $64.3 million in 2024 . Sales revenue was $70,879 thousand, and lease revenue was $731 thousand . #### Gross Profit Margin The gross profit margin for full year 2025 was 82.1%, compared to 85.8% in the prior year . The RECELL products only gross margin was 84.3% for the year . #### Operating Expenses Total operating expenses decreased by 9% to $101.4 million in 2025, from $111.8 million in 2024 . Sales and marketing expenses were - $53,138 thousand, general and administrative expenses were - $27,373 thousand, and research and development expenses were - $20,839 thousand . #### Operating Loss The operating loss for FY 2025 was - $42,534 thousand, an improvement from - $56,593 thousand in FY 2024 . #### Net Loss The net loss was - $48.6 million for full year 2025, an improvement from - $61.8 million in the prior year . ### Debt and Capital Structure In January 2026, AVITA Medical, Inc. refinanced its existing debt under a new credit facility with Perceptive Advisors LLC, securing up to $60 million of committed capital . An initial $50 million was funded, with an option for an additional $10 million through Q1 2027, subject to a revenue milestone . The new credit facility includes trailing twelve-month (TTM) revenue covenants, with an initial TTM revenue covenant of $68.5 million for Q1 2026 and $73 million for the full year 2026 . To comply with the initial TTM revenue covenant, AVITA Medical, Inc. needs to achieve $15.4 million in revenue in Q1 2026 . ### Outlook / Guidance AVITA Medical, Inc. expects full-year 2026 revenue to be in the range of $80 million to $85 million, representing an anticipated growth of approximately 12% to 19% compared to 2025 revenue . The company aims for consistent, execution-led growth quarter by quarter, focusing on deeper utilization within core burn and trauma centers . ### Related Stocks - [RCEL.US](https://longbridge.com/en/quote/RCEL.US.md) ## Related News & Research - [AVITA Medical wins BARDA contract worth up to $25.5M](https://longbridge.com/en/news/282224300.md) - [AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data | RCEL Stock News](https://longbridge.com/en/news/281926583.md) - [Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies | RCEL Stock News](https://longbridge.com/en/news/273620840.md) - [Avita Medical Targets “Progressive” 2026 Growth, Guides $80M-$85M Revenue After Headwind Year](https://longbridge.com/en/news/276815326.md) - [D. Boral Capital Issues Pessimistic Forecast for Avita Medical (NASDAQ:RCEL) Stock Price](https://longbridge.com/en/news/272745133.md)